DE60001586T2 - Diphenyl-piperidin derivate - Google Patents

Diphenyl-piperidin derivate Download PDF

Info

Publication number
DE60001586T2
DE60001586T2 DE60001586T DE60001586T DE60001586T2 DE 60001586 T2 DE60001586 T2 DE 60001586T2 DE 60001586 T DE60001586 T DE 60001586T DE 60001586 T DE60001586 T DE 60001586T DE 60001586 T2 DE60001586 T2 DE 60001586T2
Authority
DE
Germany
Prior art keywords
methyl
piperidinyl
diphenyl
chlorobenzyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60001586T
Other languages
German (de)
English (en)
Other versions
DE60001586D1 (de
Inventor
Andrew John Gilby Loughborough BAXTER
Stephen John Loughborough BROUGH
Thomas Loughborough MCINALLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of DE60001586D1 publication Critical patent/DE60001586D1/de
Application granted granted Critical
Publication of DE60001586T2 publication Critical patent/DE60001586T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE60001586T 1999-07-21 2000-07-18 Diphenyl-piperidin derivate Expired - Fee Related DE60001586T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902765 1999-07-21
SE9902765A SE9902765D0 (sv) 1999-07-21 1999-07-21 Novel compounds
PCT/GB2000/002756 WO2001005782A1 (en) 1999-07-21 2000-07-18 Novel diphenyl-piperidine derivate

Publications (2)

Publication Number Publication Date
DE60001586D1 DE60001586D1 (de) 2003-04-10
DE60001586T2 true DE60001586T2 (de) 2004-02-12

Family

ID=20416552

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001586T Expired - Fee Related DE60001586T2 (de) 1999-07-21 2000-07-18 Diphenyl-piperidin derivate

Country Status (17)

Country Link
US (1) US6566376B1 (cg-RX-API-DMAC10.html)
EP (1) EP1202984B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003505383A (cg-RX-API-DMAC10.html)
KR (1) KR20020027498A (cg-RX-API-DMAC10.html)
CN (1) CN1152873C (cg-RX-API-DMAC10.html)
AT (1) ATE233754T1 (cg-RX-API-DMAC10.html)
AU (1) AU771344B2 (cg-RX-API-DMAC10.html)
BR (1) BR0012610A (cg-RX-API-DMAC10.html)
CA (1) CA2378084A1 (cg-RX-API-DMAC10.html)
DE (1) DE60001586T2 (cg-RX-API-DMAC10.html)
IL (1) IL147149A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA02000671A (cg-RX-API-DMAC10.html)
NO (1) NO20020282L (cg-RX-API-DMAC10.html)
NZ (1) NZ516606A (cg-RX-API-DMAC10.html)
SE (1) SE9902765D0 (cg-RX-API-DMAC10.html)
WO (1) WO2001005782A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200110540B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
US10344095B2 (en) * 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments
RU2010103104A (ru) * 2007-07-02 2011-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные имидазола в качестве антагонистов рецептора ccr2
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8778616B2 (en) 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
CA2903394C (en) 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム,インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
CN108299411B (zh) * 2017-01-13 2021-02-05 中国人民解放军军事医学科学院毒物药物研究所 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
IL90858A (en) 1988-07-07 1994-08-26 Rhone Poulenc Sante Derivatives of (AZA) naphthalensultam, their preparation and compositions containing them
US5352684A (en) 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
DE4140542A1 (de) 1991-12-09 1993-06-17 Bayer Ag Piperdylmethyl substituierte chormanderivate
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6046331A (en) 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders

Also Published As

Publication number Publication date
CA2378084A1 (en) 2001-01-25
AU6001600A (en) 2001-02-05
EP1202984B1 (en) 2003-03-05
JP2003505383A (ja) 2003-02-12
CN1361775A (zh) 2002-07-31
SE9902765D0 (sv) 1999-07-21
IL147149A0 (en) 2002-08-14
US6566376B1 (en) 2003-05-20
ZA200110540B (en) 2003-03-24
KR20020027498A (ko) 2002-04-13
CN1152873C (zh) 2004-06-09
MXPA02000671A (es) 2002-07-02
NO20020282L (no) 2002-03-21
NZ516606A (en) 2003-09-26
AU771344B2 (en) 2004-03-18
NO20020282D0 (no) 2002-01-18
DE60001586D1 (de) 2003-04-10
ATE233754T1 (de) 2003-03-15
EP1202984A1 (en) 2002-05-08
BR0012610A (pt) 2002-04-09
WO2001005782A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
DE69434316T2 (de) Verfahren zur Herstellung von trisubstituierten Imidazolverbindungen mit mehreren therapeutischen Eigenschaften
DE69823858T2 (de) Amidderivate oder deren salze
DE69508093T2 (de) Substituierte piperidine für die behandlung von allergischen krankheiten
AU700837B2 (en) 1,4-di-substituted piperidine derivatives
DE60312998T2 (de) 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
RU2582338C2 (ru) Соединения пиразола в качестве ингибиторов сигма рецепторов
US6566376B1 (en) Diphenyl-piperidine derivative
DE60020560T2 (de) Substituierte pyrazol-derivate
US20040006081A1 (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
US20090149460A1 (en) New Compounds
DE602005002470T2 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
EP1228059B1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
KR101421785B1 (ko) 프로스타글란딘 d 합성 효소를 저해하는 피페라진 화합물
JP2000502690A (ja) タキキニンレセプターアンタゴニストとしての1−(1,2−ジ置換ピペリジニル)−4−置換ピペリジン誘導体
DE60201259T2 (de) Chemische verbindungen
US7683067B2 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
DE60314170T2 (de) Substituierte 4-amino-1-(pyridylmethyl)piperidine zur verwendung als muscarinrezeptor-antagonisten
DE60032016T2 (de) Cycloamin-ccr5-rezeptor-antagonisten
DE60037888T2 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
DE69414855T2 (de) N-(piperidinyl-1-alkyl)-substituierte cyclohexancarbonsäureamide als 5ht1a rezeptor antagonisten
DE60208694T2 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
DE3851388T2 (de) Substituierte N-(3-Hydroxy-4-piperidinyl)benzamide.
JP2005513017A (ja) ケモカイン受容体(特にccr)活性のモジュレーターとしてのピペリジン誘導体とその使用
EP1611094B1 (de) Pyrazolverbindungen
DE69415672T2 (de) Azolyl-cyclische aminderivate mit immunomodulierender wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee